



IMMURON LIMITED

(ASX: IMC)

Results of General Meeting

Tuesday, 27th May 2014

The Company wishes to advise that all resolutions were unanimously carried on show of hands.

In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following information is provided in relation to the resolutions considered by Members of the Company at the General Meeting held today.

Resolution		For	Against	Abstain	Proxy's Discretion*	Total Valid Proxies Received
1	Ratification of Prior Issue of Unlisted Options	1,435,833,857	64,958,931	325,415	71,149,744	1,571,942,532
2	Approve the Issue of Shares to Grandlodge Pty Ltd or its Nominee	919,873,081	55,040,599	526,204,523	71,149,744	1,046,063,424
3	Approve the Issue of Unlisted Options to Reza Moussakhani or his Nominee	1,445,736,189	55,040,599	291,415	71,199,744	1,571,976,532
4	Adoption of New Constitution	1,259,045,749	54,847,259	187,175,195	71,199,744	1,385,092,752

* The Chairman voted undirected proxies in his control in favour of all resolutions.

For and on behalf of the Board;

Peter Vaughan
Company Secretary

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron's technology platform products all have a very high safety profile. The company's current products and product candidates address infectious diseases of the gastrointestinal tract as well as chronic diseases. Immuron has an on-market product, Travelan[®], for preventing travellers' diarrhoea. Immuron also has a phase 2 clinical product candidate for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steatohepatitis or NASH. Immuron's main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).